全球基础设施ETF-iShares(IGF)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IGF 全球基础设施ETF-iShares

已收盘 05-06 16:00:00 EDT

48.74

+0.26

+0.54%

最高48.79	最低48.60	成交量21.98万
今开48.64	昨收48.48	日振幅0.41%
总市值36.51亿	流通市值36.51亿	总股本7,490万
成交额1,070万	换手率0.29%	流通股本7,490万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"IGF","market":"US","secType":"STK","nameCN":"全球基础设施ETF-iShares","latestPrice":48.74,"timestamp":1715025600000,"preClose":48.48,"halted":0,"volume":219794,"delay":0,"floatShares":74900000,"shares":74900000,"eps":0,"marketStatus":"已收盘","marketStatusCode":5,"change":0.26,"latestTime":"05-06 16:00:00 EDT","open":48.64,"high":48.7931,"low":48.595,"amount":10704159.02078,"amplitude":0.004086,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"exchange":"ARCA","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1715068800000},"adr":0,"adjPreClose":48.48,"adrRate":0,"sharesOutstanding":74900000,"nav":48.479,"aum":3631075377.3,"bidAskSpread":0.000547,"preHourTrading":{"tag":"盘前","latestPrice":48.48,"preClose":48.48,"latestTime":"08:00 EDT","volume":1,"amount":48.48,"timestamp":1714996847840},"volumeRatio":0.686347},"requestUrl":"/m/hq/s/IGF/wiki","defaultTab":"wiki","newsList":[{"id":"2417203694","title":"信达生物在2024年亚太眼科学会年会和国际内分泌学大会上口头报告IBI311（抗IGF-1R单抗）的两项临床研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2417203694","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2417203694?lang=zh_cn&edition=full","pubTime":"2024-03-07 10:43","pubTimestamp":1709779380,"startTime":"0","endTime":"0","summary":"研究期间，IBI311各剂量组抗药抗体均检测为阴性。提示健康受试者接受不同剂量下单次静脉注射IBI311的安全性和耐受性良好，且PK特征支持后续临床开发的剂量选择。在12周后，所有受试者将继续接受IBI311治疗，持续至第21周。安全性：总体安全性良好，绝大多数AE为轻度或中度，IBI311组无导致药物停用/暂停的治疗期不良事件。目前IBI311 的III期临床试验已经完成，主要终点顺利达成。尤其是对于合并显著突眼的TED，靶向IGF-1R的替妥尤单抗可作为首选。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4355203_ZH55203_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414815217","title":"港股异动 | 信达生物(01801)再涨超4% IGF-1R抗体III期临床达主要终点 计划递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2414815217","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2414815217?lang=zh_cn&edition=full","pubTime":"2024-02-27 11:52","pubTimestamp":1709005959,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物再涨超4%，月内累涨超30%。消息面上，2月20日，信达生物宣布其研发的重组抗胰岛素样生长因子1受体抗体注射液在中国甲状腺眼病受试者中开展的III期注册临床研究达成主要终点。高盛维持信达生物\"买入\"评级，目标价由57.4港元调高至60.66港元。高盛估计，信达生物新药IBI311治疗效果令人满意，预计可于2025年于内地推出上市，2033年销售峰值达10亿元人民币，这假设约有2.5万名甲状腺眼病病人受药。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1077314.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2412167711","title":"信达生物宣布IBI311（抗IGF-1R抗体）治疗甲状腺眼病的III期临床研究（RESTORE-1）达成主要终点，计划将递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2412167711","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2412167711?lang=zh_cn&edition=full","pubTime":"2024-02-20 08:00","pubTimestamp":1708387200,"startTime":"0","endTime":"0","summary":"信达生物计划向国家药品监督管理局药品审评中心递交IBI311治疗TED的新药上市申请。整个研究期间IBI311整体安全性良好，未发生严重不良事件。RESTORE-1研究III期阶段的疗效趋势和安全性特征与II期阶段结果高度一致。当前国内尚无用于治疗甲状腺眼病的靶向药物获批，治疗手段有限。信达生物管线布局一直以未满足医学需求为导向，公司自主研发的基于IGF-1R靶点的单克隆抗体IBI311在RESTORE-1研究中展示出治疗TED效果显著、安全性良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4339801_ZH39801_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2401607303","title":"发达国家提高关键矿产资源供应保障能力的经验与启示","url":"https://stock-news.laohu8.com/highlight/detail?id=2401607303","media":"社科院工业经济...","top":-1,"share":"https://www.laohu8.com/m/news/2401607303?lang=zh_cn&edition=full","pubTime":"2024-01-05 10:43","pubTimestamp":1704422624,"startTime":"0","endTime":"0","summary":"作者周维富 陈文静发表于《自然资源情报》网络首发CNKI:2024-1-3摘要近年来，为保障关键矿产资源的安全供应，西方发达国家根据国际形势变化不断完善关键矿产资源保障的制度，不断完善关键矿产资源评价指标体系，不断调整优化关键矿产资源战略和关键矿产清单，不断调整优化关键矿产资源战略储备，持续推动关键矿产资源的技术...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OpLTVFmVH_ufT_nRPM4txfY_0DeKJaM3qwlqDZ5BXD56UAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OpLTVFmVH_ufT_nRPM4txfY_0DeKJaM3qwlqDZ5BXD56UAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240105A02TTY00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240105A02TTY00","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0204},{"period":"1month","weight":0.0181},{"period":"3month","weight":0.0678},{"period":"6month","weight":0.0951},{"period":"1year","weight":0.0044},{"period":"ytd","weight":0.0304}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.529412,"avgChangeRate":-0.004463},{"month":2,"riseRate":0.705882,"avgChangeRate":-0.00609},{"month":3,"riseRate":0.764706,"avgChangeRate":0.012882},{"month":4,"riseRate":0.823529,"avgChangeRate":0.024338},{"month":5,"riseRate":0.470588,"avgChangeRate":0.000996},{"month":6,"riseRate":0.3125,"avgChangeRate":-0.017618},{"month":7,"riseRate":0.75,"avgChangeRate":0.016932},{"month":8,"riseRate":0.4375,"avgChangeRate":-0.013602},{"month":9,"riseRate":0.375,"avgChangeRate":-0.012957},{"month":10,"riseRate":0.625,"avgChangeRate":0.001537},{"month":11,"riseRate":0.375,"avgChangeRate":0.006371},{"month":12,"riseRate":0.5625,"avgChangeRate":0.003059}],"exchange":"ARCA","name":"全球基础设施ETF-iShares","nameEN":"iShares Global Infrastructure ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"全球基础设施ETF-iShares(IGF)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供全球基础设施ETF-iShares(IGF)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"全球基础设施ETF-iShares,IGF,全球基础设施ETF-iShares股票,全球基础设施ETF-iShares股票老虎,全球基础设施ETF-iShares股票老虎国际,全球基础设施ETF-iShares行情,全球基础设施ETF-iShares股票行情,全球基础设施ETF-iShares股价,全球基础设施ETF-iShares股市,全球基础设施ETF-iShares股票价格,全球基础设施ETF-iShares股票交易,全球基础设施ETF-iShares股票购买,全球基础设施ETF-iShares股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"全球基础设施ETF-iShares(IGF)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供全球基础设施ETF-iShares(IGF)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}